SAN DIEGO, March 4, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will
participate in two upcoming investor conferences.
- The 39th Annual Cowen Healthcare Conference on
Monday, March 11 at 4:50 p.m. ET / 1:50 p.m.
PT in Boston, MA. Dr.
Helen Torley, president and chief
executive officer, will present an overview of the company.
- The Barclays Global Healthcare Conference on Tuesday, March 12 at 3:50
p.m. ET / 12:50 p.m. PT in
Miami, FL. Laurie Stelzer, senior vice president and chief
financial officer, will present a brief overview of the company
followed by a question and answer session.
A live webcast of each presentation can be accessed through the
"Investors" section of www.halozyme.com, and a recording will be
made available for 90 days following each event. To access a live
webcast, please visit Halozyme's website approximately 15 minutes
prior to the presentation to register and download any necessary
audio software.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a
unique approach to targeting solid tumors, allowing increased
access of co-administered cancer drug therapies to the tumor in
animal models. PEGPH20 is currently in development for the
treatment of several cancers and has the potential to be used in
combination with different types of cancer therapies. In addition
to its proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical and
biotechnology companies, including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its
ENHANZE® drug delivery technology. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-upcoming-investor-conferences-300805350.html
SOURCE Halozyme Therapeutics, Inc.